Macrophage migration inhibitory factor involvement in breast cancer (Review)

Richard,Vincent; Kindt,Nadège; Saussez,Sven

doi:10.3892/ijo.2015.3185

Macrophage migration inhibitory factor involvement in breast cancer (Review)

Authors:
- Vincent Richard
- Nadège Kindt
- Sven Saussez
View Affiliations

Affiliations: Laboratory of Anatomy and Cell Biology, Faculty of Medicine and Pharmacy, University of Mons, B-7000 Mons, Belgium
Published online on: September 24, 2015 https://doi.org/10.3892/ijo.2015.3185
Pages: 1627-1633
Copyright: © Richard et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Macrophage migration inhibitory factor (MIF) is a pleiotropic inflammatory cytokine involved in many cellular processes and in particular carcinogenesis. Here, we review the experimental and clinical published data on MIF and its pathways in breast cancer. Experimental data show that MIF is overexpressed in breast cancer cells (BCC) due, at least partly, to its stabilization by HSP90 and upregulation by HIF-1α. MIF interacts with its main receptor CD74 and its co-receptor CXCR-4, both overexpressed, promoting cell survival by PI3K/Akt activation, a possible link with EGFR and HER2 pathways and inhibition of autophagy. Besides these auto- and paracrine effects on BCC, MIF interacts with BCC microenvironment by several mechanisms: immunomodulation by increasing the prevalence of immune suppressive cells, neo-angiogenesis by its link to HIF-1, and finally BCC transendothelial migration. Clinical studies show higher levels of MIF in breast cancer patients serum compared to healthy volunteers but without obvious clinical significance. In breast cancer tissue, MIF and CD74 are overexpressed in the cancer cells and in the stroma but correlations with classical prognostic factors or survival are elusive. However, an inverse correlation with the tumor size for stromal MIF and a positive correlation with the triple receptor negative tumor status for stromal CD74 seem to be showed. This set of experimental and clinical data shows the involvement of MIF pathways in breast carcinogenesis. Several anti-MIF targeted strategies are being explored in therapeutic goals and should merit further investigations.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Pietras K and Östman A: Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res. 316:1324–1331. 2010. View Article : Google Scholar : PubMed/NCBI
3	Mitchell RA and Yaddanapudi K: Stromal-dependent tumor promotion by MIF family members. Cell Signal. 26:2969–2978. 2014. View Article : Google Scholar : PubMed/NCBI
4	Conroy H, Mawhinney L and Donnelly SC: Inflammation and cancer: Macrophage migration inhibitory factor (MIF) - the potential missing link. QJM. 103:831–836. 2010. View Article : Google Scholar : PubMed/NCBI
5	Donn RP and Ray DW: Macrophage migration inhibitory factor: Molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol. 182:1–9. 2004. View Article : Google Scholar : PubMed/NCBI
6	Swope M, Sun HW, Blake PR and Lolis E: Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J. 17:3534–3541. 1998. View Article : Google Scholar : PubMed/NCBI
7	Li XJ, Luo Y and Yi YF: P115 promotes growth of gastric cancer through interaction with macrophage migration inhibitory factor. World J Gastroenterol. 19:8619–8629. 2013. View Article : Google Scholar :
8	Zernecke A, Bernhagen J and Weber C: Macrophage migration inhibitory factor in cardiovascular disease. Circulation. 117:1594–1602. 2008. View Article : Google Scholar : PubMed/NCBI
9	Kim H, Lee S, Kim HJ, Kong MH, Kim YR, Kang SH, Lee K, Leng L, Lee B, Park CG, et al: Elevated levels of macrophage migration inhibitory factor in women with metabolic syndrome. Horm Metab Res. 43:642–645. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, Rodriguez A, Johnson BD, Megalizzi V, Decaestecker C, Laurent G, et al: Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: Clinical and experimental studies. J Cancer Res Clin Oncol. 139:727–737. 2013. View Article : Google Scholar : PubMed/NCBI
11	Wang D, Luo L, Chen W, Chen LZ, Zeng WT, Li W and Huang XH: Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma. Oncol Rep. 31:1199–1204. 2014.
12	Krockenberger M, Kranke P, Häusler S, Engel JB, Horn E, Nürnberger K, Wischhusen J, Dietl J and Hönig A: Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis. Anticancer Res. 32:5233–5238. 2012.PubMed/NCBI
13	Tan L, Ye X, Zhou Y, Yu M, Fu Z, Chen R, Zhuang B, Zeng B, Ye H, Gao W, et al: Macrophage migration inhibitory factor is overexpressed in pancreatic cancer tissues and impairs insulin secretion function of β-cell. J Transl Med. 12:922014. View Article : Google Scholar
14	He XX, Yang J, Ding YW, Liu W, Shen QY and Xia HH: Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: Potential role of MIF in gastric carcinogenesis. Gut. 55:797–802. 2006. View Article : Google Scholar : PubMed/NCBI
15	Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, Chen Z, Murphy JW, Lolis E, et al: CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 25:595–606. 2006. View Article : Google Scholar : PubMed/NCBI
16	Lee CY, Su MJ, Huang CY, Chen MY, Hsu HC, Lin CY and Tang CH: Macrophage migration inhibitory factor increases cell motility and up-regulates αvβ3 integrin in human chondrosar-coma cells. J Cell Biochem. 113:1590–1598. 2012.
17	Mitchell RA: Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal. 16:13–19. 2004. View Article : Google Scholar
18	Xin D, Rendon BE, Zhao M, Winner M, McGhee Coleman A and Mitchell RA: The MIF homologue D-dopachrome tautomerase promotes COX-2 expression through β-catenin-dependent and -independent mechanisms. Mol Cancer Res. 8:1601–1609. 2010. View Article : Google Scholar : PubMed/NCBI
19	Meyer-Siegler K: COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4-2b prostate cancer cells. Mol Med. 7:850–860. 2001.
20	Xia HH, Zhang ST, Lam SK, Lin MC, Kung HF and Wong BC: Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and effects of bile acids and NSAIDs. Carcinogenesis. 26:11–15. 2005. View Article : Google Scholar
21	Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H and Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62:632–635. 2002.PubMed/NCBI
22	de Pedro M, Baeza S, Escudero MT, Dierssen-Sotos T, Gómez-Acebo I, Pollán M and Llorca J: Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: A meta-analysis. Breast Cancer Res Treat. 149:525–536. 2015. View Article : Google Scholar : PubMed/NCBI
23	Tarnowski M, Grymula K, Liu R, Tarnowska J, Drukala J, Ratajczak J, Mitchell RA, Ratajczak MS and Kucia M: Human Rhabdomyosarcomas secrete MIF that modulates metastatic behavior of tumor cells and inhibits recruitment of cancer associated fibroblasts. Mol Cancer Res. 8:1328–1343. 2010. View Article : Google Scholar : PubMed/NCBI
24	Martinez LM, Vallone VBF, Labovsky V, Choi H, Hofer EL, Feldman L, Bordenave RH, Batagelj E, Dimase F, Villafañe AR, et al: Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases. Clin Exp Metastasis. 31:213–232. 2014. View Article : Google Scholar
25	Verjans E, Noetzel E, Bektas N, Schûtz AK, Lue H, Lennartz B, Hartmann A, Dahl E and Bernhagen J: Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer. 9:2302009. View Article : Google Scholar : PubMed/NCBI
26	Schulz R, Streller F, Scheel AH, Rüschoff J, Reinert MC, Dobbelstein M, Marchenko ND and Moll UM: HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer. Cell Death Dis. 5:e9802014. View Article : Google Scholar : PubMed/NCBI
27	Bando H, Toi M, Kitada K and Koike M: Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomed Pharmacother. 57:333–340. 2003. View Article : Google Scholar : PubMed/NCBI
28	Larsen M, Tazzyman S, Lund EL, Junker N, Lewis CE, Kristjansen PE and Murdoch C: Hypoxia-induced secretion of macrophage migration-inhibitory factor from MCF-7 breast cancer cells is regulated in a hypoxia-inducible factor-independent manner. Cancer Lett. 265:239–249. 2008. View Article : Google Scholar : PubMed/NCBI
29	Lue H, Dewor M, Leng L, Bucala R and Bernhagen J: Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signal. 23:135–144. 2011. View Article : Google Scholar
30	Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M and Yamamoto N: Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 60:273–276. 2006. View Article : Google Scholar : PubMed/NCBI
31	Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Lüscher B and Bernhagen J: Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 26:5046–5059. 2007. View Article : Google Scholar : PubMed/NCBI
32	Simpson KD, Templeton DJ and Cross JV: Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol. 189:5533–5540. 2012. View Article : Google Scholar : PubMed/NCBI
33	Lim S, Choong LY, Kuan CP, Yunhao C and Lim YP: Regulation of macrophage inhibitory factor (MIF) by epidermal growth factor receptor (EGFR) in the MCF10AT model of breast cancer progression. J Proteome Res. 8:4062–4076. 2009. View Article : Google Scholar : PubMed/NCBI
34	Drews-Elger K, Iorns E, Dias A, Miller P, Ward TM, Dean S, Clarke J, Campion-Flora A, Rodrigues DN, Reis-Filho JS, et al: Infiltrating S100A8⁺ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome. Breast Cancer Res Treat. 148:41–59. 2014. View Article : Google Scholar : PubMed/NCBI
35	Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X, Zhang Y and Wang S: Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett. 261:147–157. 2008. View Article : Google Scholar : PubMed/NCBI
36	Oda S, Oda T, Nishi K, Takabuchi S, Wakamatsu T, Tanaka T, Adachi T, Fukuda K, Semenza GL and Hirota K: Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS One. 3:e22152008. View Article : Google Scholar : PubMed/NCBI
37	Wu MY, Fu J, Xu J, O'Malley BWO and Wu RC: Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor. Cell Res. 22:1003–1021. 2012. View Article : Google Scholar : PubMed/NCBI
38	Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M and Moll UM: Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med. 209:275–289. 2012. View Article : Google Scholar : PubMed/NCBI
39	Fujita Y, Islam R, Sakai K, Kaneda H, Kudo K, Tamura D, Aomatsu K, Nagai T, Kimura H, Matsumoto K, et al: Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors. Invest New Drugs. 30:1878–1886. 2012. View Article : Google Scholar
40	Sprouse AA and Herbert BS: Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells. Anticancer Res. 34:5363–5374. 2014.PubMed/NCBI
41	Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M and Toi M: Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread. Jpn J Cancer Res. 93:389–396. 2002. View Article : Google Scholar : PubMed/NCBI
42	Richard V, Kindt N, Decaestecker C, Gabius HJ, Laurent G, Noël JC and Saussez S: Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer. Oncol Rep. 32:523–529. 2014.PubMed/NCBI
43	Fersching DM, Nagel D, Siegele B, Salat C, Heinemann V, Holdenrieder S and Stoetzer OJ: Apoptosis-related biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy. Anticancer Res. 32:2047–2058. 2012.PubMed/NCBI
44	Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lokshin AE and Lo JY: Do serum biomarkers really measure breast cancer? BMC Cancer. 9:1642009. View Article : Google Scholar : PubMed/NCBI
45	Opstal-van Winden AW, Rodenburg W, Pennings JLA, van Oostrom CTM, Beijnen JH, Peeters PHM, van Gils CH and de Vries A: A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci. 13:13587–13604. 2012. View Article : Google Scholar : PubMed/NCBI
46	Choi J, Jung WH and Koo JS: Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. Pathobiology. 80:41–52. 2013. View Article : Google Scholar
47	Catteau X, Simon P, Vanhaeverbeek M and Noël JC: Variable stromal periductular expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast. PLoS One. 8:e577732013. View Article : Google Scholar : PubMed/NCBI
48	Catteau X, Simon P and Noël JC: Myofibroblastic stromal reaction and lymph node status in invasive breast carcinoma: possible role of the TGF-β1/TGF-βR1 pathway. BMC Cancer. 4:4992014. View Article : Google Scholar
49	Catteau X, Simon P and Noël JC: Myofibroblastic reaction is a common event in metastatic disease of breast carcinoma: A descriptive study. Diagn Pathol. 9:1962014. View Article : Google Scholar : PubMed/NCBI
50	Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol. 26:259–271. 2015. View Article : Google Scholar
51	Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, et al: A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer. 14:154–160. 2014. View Article : Google Scholar : PubMed/NCBI
52	Baxalta US Inc. (sponsor). Phase I Study of anti-Macrophage Migration Inhibitory Factor antibody in solid Tumors. ClinicalTrials.gov identifier: NCT01765790. https://clinicaltrials.gov/ct2/show/NCT01765790.
53	Berkova Z, Tao RH and Samaniego F: Milatuzumab - a promising new immunotherapeutic agent. Expert Opin Investig Drugs. 19:141–149. 2010. View Article : Google Scholar
54	Howe LR: Inflammation and breast cancer. Cyclooxygenase/ prostaglandin signaling and breast cancer. Breast Cancer Res. 9:2102007. View Article : Google Scholar
55	Majumder M, Xin X, Liu L, Girish GV and Lala PK: Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Cancer Sci. 105:1142–1151. 2014. View Article : Google Scholar : PubMed/NCBI